{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-084852","form_type":"8-K","ticker":null,"cik":"0001580063","company_name":"BIORA THERAPEUTICS, INC.","filed_at":"2024-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.058743+00:00","generated_at":"2026-06-04T03:33:36.495120+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biora prices $6M registered direct offering of 5.45M shares at $1.10; warrants also issued","bullets":["Gross proceeds of ~$6M from sale of 5,454,548 shares at $1.10 per share.","Issued warrants to purchase 5,454,548 shares at $1.10; exercisable after stockholder approval.","Amended existing warrants to lower exercise price to $1.10 and extend term to 5 years post-approval.","Entered voting agreements with Athyrium and officers/directors to support stockholder approval.","Expected closing on April 3, 2024; H.C. Wainwright acted as placement agent."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-084852","json":"https://secwatch.observer/filing/0001193125-24-084852.json","markdown":"https://secwatch.observer/filing/0001193125-24-084852.md","text":"https://secwatch.observer/filing/0001193125-24-084852.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1580063/000119312524084852/0001193125-24-084852-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1580063/000119312524084852/d816753d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T03:33:36.495120+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"acfe644e7caf6b4cda7bc93fb52980a92252f952","claim":"BIORA THERAPEUTICS, INC. entered into Purchase Agreement with certain institutional and accredited investors valued at approximately $6 million (effective 2024-03-31).","evidence_excerpt":"On March 31, 2024, Biora Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement with certain institutional and accredited investors (the “Purchase Agreement”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1580063/000119312524084852/0001193125-24-084852-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional and accredited investors"},{"label":"Value","value":"approximately $6 million"},{"label":"Effective","value":"2024-03-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}